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ABSTRACT 24 
Single doses of resveratrol have previously been shown to increase cerebral blood flow (CBF) with 25 
no clear effect on cognitive function or mood in healthy adults. Chronic resveratrol consumption 26 
may increase the poor bioavailability of resveratrol or otherwise potentiate its psychological effects. 27 
In this randomised, double-blind, placebo-controlled, parallel-groups study a total of 60 adults aged 28 
between 18-30yrs received either placebo or resveratrol for 28 days. On the 1
st
 and 28
th
 day of 29 
treatment the performance of cognitively demanding tasks (Serial subtractions, Rapid Visual 30 
Information Processing and 3-Back) (N= 41 complete datasets) were assessed, alongside blood-31 
pressure (N= 26) and acute (Near-infrared Spectroscopy [NIRS]) and chronic (Trans-Cranial 32 
Doppler [TCD]) measures of CBF (N= 46). Subjective mood, sleep quality and health 33 
questionnaires were completed at weekly intervals (N= 53/54). The results showed that the 34 
cognitive effects of resveratrol on day 1 were restricted to more accurate but slower Serial 35 
Subtraction task performance. The only cognitive finding on day 28 was a beneficial effect of 36 
resveratrol on the accuracy of the 3-Back task prior to treatment consumption. Subjective ratings of 37 
‘fatigue’ were significantly lower across the entire 28 days in the resveratrol condition. Resveratrol 38 
also resulted in modulation of CBF parameters on day 1, as assessed by NIRS, and significantly 39 
increased diastolic BP on day 28. Levels of resveratrol metabolites were significantly higher both 40 
before and after the day’s treatment on day 28, in comparison to day 1. These results confirm the 41 
acute CBF effects of resveratrol and the lack of interpretable cognitive effects.  42 
 43 
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 53 
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INTRODUCTION 54 
Resveratrol (3, 4’, 5 trihydroxystilbene) is a polyphenolic secondary metabolite produced within 55 
plants in response to a range of environmental stressors
(1)
. Previous investigations in young, healthy 56 
humans have demonstrated significantly increased cerebral blood flow (CBF) after acute resveratrol 57 
supplementation
(2)
 which is likely mediated by the ability of resveratrol to modulate nitric oxide 58 
(NO) synthesis
(3)
. In line with this, oral consumption has been shown to enhance endothelium-59 
dependent relaxation in rats
(4, 5)
, and improve flow-mediated dilatation in overweight/obese 60 
humans
(6)
. An increase in blood-borne neural metabolic substrates such as oxygen
(7)
 and glucose
(8)
 61 
have been shown to enhance aspects of cognitive performance in healthy, young humans. However, 62 
to date there is no evidence that cognitive function is modulated during acute, resveratrol-mediated 63 
increases in CBF. 64 
One potential explanation for this lack of cognitive effects is the rapid metabolism and poor 65 
bioavailability of oral resveratrol
(9)
 which might reduce its potential bioactivity. Pharmacokinetic 66 
studies have demonstrated plasma Cmax levels of resveratrol metabolites between 0.9-3.7 µM 67 
following a single oral dose of 500mg resveratrol
(10)
 with levels of the parent compound at trace, or 68 
undetectable concentrations
(2, 10-13)
 after acute, bolus supplementation. Conversely, results from 3 69 
preclinical chemopreventive efficacy papers suggest that repeated low daily doses of resveratrol (up 70 
to 2mg/kg) are sufficient to produce peak plasma concentrations of aglycone resveratrol of up to 71 
2µM, potentially exerting beneficial chemopreventive effects
(14)
 possibly as a result of a cumulative 72 
increase in plasma levels of resveratrol.  73 
Thus the current study investigated the effects of 28 day supplementation with 500mg resveratrol in 74 
healthy adults with the hypothesis being that daily consumption of this polyphenol, over an 75 
extended period, may increase bioavailability in terms of plasma levels, and potentiate any effects 76 
on cognitive performance and CBF. In the current study continuous wave (CW) Near-Infrared 77 
Spectroscopy (NIRS) was utilized to monitor acute changes in CBF in the prefrontal cortex during 78 
the performance of cognitive tasks that activate this brain region. This technique was combined 79 
with Trans-cranial Doppler sonography (TCD), applied to the middle cerebral artery (MCA), which 80 
provides a measure of acute and chronic changes in global CBF velocity (CBFV) and which has 81 
been converged successfully with NIRS previously 
(15)
. Resveratrol has previously been shown to 82 
interact with a number of diffuse, health related parameters such as antioxidant and anti-83 
inflammatory status
(16, 17)
, monoamine oxidase-A and B activity
(18)
 and Peroxisome proliferator-84 
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activated receptor gamma coactivator 1-alpha PGC-1α(19) production. Hence, the current study also 85 
assessed health, mood and sleep parameters via questionnaires.  86 
 87 
 88 
EXPERIMENTAL METHODS 89 
Participants 90 
All participants reported themselves to be in good health and free from illicit drugs, alcohol, 91 
prescription medication and herbal extracts/food supplements at each assessment. Participants 92 
confirmed that they would also abstain from the latter for the duration of the study and that any 93 
changes in medication or health status would be reported to the researcher when they occurred. 94 
Participants who had suffered a head injury, neurological disorder or neuro-developmental disorder 95 
were excluded from participation, as were those who did not have English as their 1
st
 language, or 96 
had any relevant food allergies or intolerances, digestive problems, smoked tobacco, drank 97 
excessive amounts of caffeine (more than 600mg/day as assessed by a caffeine consumption 98 
questionnaire), took illicit social drugs, were pregnant, seeking to become so, or were breast 99 
feeding. 100 
The study received ethical approval from the Northumbria University Psychology department 101 
(within the Faculty of Health and Life Sciences) ethics committee (reference: SUB16_EW_1010; 102 
date approved 11/11/2010) and was conducted according to the Declaration of Helsinki (1964). All 103 
participants gave their written informed consent prior to their inclusion in the study. 104 
See table 1. for participant composition (broken down per analysis).  105 
Table 1. Participant composition. Table displays number of participants included in each measure. Sixty 106 
participants were originally recruited to take part in all aspects of assessments apart from the blood pressure 107 
measurement which utilized only 30 participants due to the potential disruption this may have caused to 108 
NIRS measurement. Reasons for excluding data from analyses include: technical problems with equipment 109 
(affecting aspects of 12 cognitive performance data sets, 14 NIRS, 14 TCD recordings (namely not being 110 
able to locate a consistent, 5 minute, blood flow trace in the latter and data which was outside of the 111 
calculated standard deviations of this cohort, and may suggest an ill-fitting headband, with regards NIRS) 112 
and 6 blood pressure readings) and participants not complying with proper completion of measures/ omitting 113 
to respond (affecting aspects of 7 cognitive performance data sets, 7 responses from the GHQ, 6 from the 114 
POMS, 7 from the PSQI, 5 from the food consumption questionnaire and 3 from the treatment guess 115 
response). 116 
 117 
 118 
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 130 
Treatments 131 
Over the course of this 28 day supplementation study, participants received either 500mg pure 132 
trans-resveratrol (TransmaxTM by BiotiviaTM with a guaranteed purity of 98%. Also containing 10mg 133 
piperine per capsule), or an inert placebo (methyl cellulose), once daily; with the treatment 134 
allocation dictated by Latin square. Participants were instructed to consume their daily capsule in 135 
the morning and preferably with breakfast. 136 
Participants consumed their first and last capsule of treatment during the two lab visits and were 137 
instructed to self-supplement every day in the interim. Participants kept a treatment log during this 138 
time, noting down the time of capsule consumption every day. A treatment pot containing 32 139 
capsules was given to each participant at the end of visit 1- enough for 28 days of supplementation 140 
plus extra in case of loss/continued supplementation due to unforeseen circumstances/and to verify 141 
compliance. 142 
All treatments were administered in identical green vegetarian capsules with the BiotiviaTM logo and 143 
presented in identical white treatment pots with only the participant number to identify them. All 144 
treatments were produced by BiotiviaTM, prepared by the lead investigator and coded by a third 145 
party who had no further involvement in any aspect of the study. No member of the investigational 146 
team was aware of the contents of the capsules until a blind-data review was completed.  147 
 148 
Measure            
(Number participants) 
Female/Male 
Mean age    
(Age range) 
Right handed/ 
Left handed 
Placebo/ 
Resveratrol 
Overall recruited 
(N=60) 
51/9 20.52 (18-29) 53/7 30/30 
Cognitive performance 
(N=41) 
36/5 20.00 (18-27) 35/6 19/22 
NIRS (N=46) 39/7 20.45 (18-29) 39/7 24/22 
TCD (N=46) 40/6 20.08 (18-29) 40/6 21/25 
Blood pressure (N=24) 21/3 20.75 (18-29) 21/3 15/9 
GHQ (N=53) 45/8 20.17 (18-29) 46/7 28/25 
POMS (N=54) 46/8 20.07 (18-29) 47/7 28/26 
PSQI (N=53) 45/8 20.15 (18-29) 47/6 28/25 
Food consumption 
(N=55) 
47/8 20.15 (18-29) 48/7 29/26 
Treatment guess 
(N=57) 
49/8 20.25 (18-29) 50/7 28/29 
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Measures of cerebral-blood flow (CBF) 149 
Two complementary techniques were utilised: 150 
Acute changes in CBF - Near-Infrared spectroscopy (NIRS) 151 
NIRS is non-invasive brain imaging technique predicated on the absorption by oxygenated and 152 
deoxygenated haemoglobin of differing wavelengths of infra-red light, introduced through the intact 153 
scalp/skull. Continuous-wave NIRS (CW-NIRS) can be used to assess acute changes in local CBF, 154 
as indexed by concentration changes in total haemoglobin during a single continuous recording 155 
session, See
(2)
 for full description of the methods employed here. Given that CW-NIRS generates 156 
concentration change data that is intrinsically baseline-adjusted to the concentration immediately 157 
prior to the first data point in the recording session, it cannot be used to quantify gross changes in 158 
CBF parameters that take place between two separate recording sessions. In this instance the change 159 
from baseline data generated by the NIRS system was subjected to a second  baseline adjustment by 160 
creating ‘change from baseline’ data with respect to the 10 minutes of NIRS data collected 161 
immediately prior to the treatment- this provided a more accurate baseline measure of immediately 162 
pre-treatment NIRS parameters. All subsequent NIRS data was collapsed into 2 minute epochs (20 163 
resting period epochs spanning 0- 40 min and 20 task period epochs spanning 40- 80 min).   164 
 165 
Chronic changes in CBF - Trans-cranial Doppler sonography (TCD) 166 
Given the inability of CW-NIRS to measure chronic changes in CBF parameters, a second measure 167 
of CBF was also employed. Trans-cranial Doppler sonography (TCD) is a non-invasive method of 168 
measuring cerebral blood flow velocity (CBFV) through the basal intracerebral vessels through the 169 
intact skull
(20)
 and was utilized at pre- and post-dose time points on day 1 and day 28. Pulses of 170 
ultrasound penetrate the skull at a number of ‘acoustic windows’, which include: temporal, orbital, 171 
foraminal and submandibular, insonating vessels at particular depths, with the returning ‘echo’ 172 
displayed as a Doppler waveform
(21)
. The mean velocity, peak systolic velocity, diastolic velocity, 173 
and pulsatility index (all cm/sec) of the insonated vessel are provided; indicating the speed of the 174 
flow of blood and the variability of blood velocity. 175 
TCD has been utilized to investigate blood flow abnormalities in a number of haematological; e.g. 176 
stroke risk in sickle cell patients
(22)
, and vascular; e.g. cerebrovascular reactivity in degenerative and 177 
vascular dementia
(23)
, disorders as well as investigating the relationship between brain activity (in 178 
response to cognitive tasks) and blood flow velocity in healthy participants
(24)
 and the CBFV 179 
response to pharmacological interventions; e.g. caffeine
(25)
 and drugs; e.g. in cocaine abusers
(26)
.  180 
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In the current study, CBFV was measured with participants sitting in a reclined position in a quiet 181 
room. A trans-temporal acoustic window was utilized for assessment of the right middle cerebral 182 
artery (MCA) using pulsed TCD (Digi-LiteTM, RIMED) with a 2MHz probe held in place by a light, 183 
mounted head frame. This device provides mean velocity, peak systolic velocity, diastolic velocity, 184 
and pulsatility index information every 30 seconds; equating to ~10 values across the 5 minute 185 
recording utilized here, for each of the 4 aforementioned variables. These were averaged to give 1 186 
value for that time-point (pre- and post-dose on day 1 and pre- and post-dose on day 28) for 187 
statistical analysis.   188 
 189 
Cognitive tasks 190 
The computerised battery of cognitive tasks (which all, to a greater or lesser extent, activate the 191 
prefrontal cortex: Serial subtractions
(27)
; RVIP
(28)
; 3-Back
(29)
) were delivered on a laptop using the 192 
Computerised Mental Performance Assessment System (COMPASS, University of Northumbria) 193 
software, and comprised: 194 
Serial subtractions (2 mins each of serial 7s, 13s and 17s):  195 
Rapid Visual Information Processing [RVIP] (2 mins):  196 
Both the serial subtraction and RVIP task are described in detail in
(2)
. 197 
3-back: The 3-back version of this task was used in this paradigm, requiring participants to indicate 198 
whether the letter presented on screen was also present 3 letters back in the letter sequence. 199 
Participants must respond by pressing the ‘yes’ or ‘no’ button on the response box, to each letter, as 200 
quickly as they can. This task lasts for 2 minutes and is scored for accuracy and reaction time. 201 
 202 
Questionnaires 203 
Food consumption questionnaire: 204 
A non-validated food consumption questionnaire was utilized to collect information on the general 205 
diet of participants (e.g. ‘How many portions of fruit and vegetables did you eat on an average day 206 
in the past week?’) and specifically polyphenol/resveratrol consumption (e.g. ‘In the entire previous 207 
week, on how many occasions have you eaten a portion of berries or grapes?’). The questionnaire 208 
consisted of 13 questions with several also relating to compliance (e.g. ‘Was treatment consumed 209 
with breakfast and/or before 9:30am every day in the past week?’) and medication (‘Have you 210 
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consumed any medication in the past week? If so, please state the medication, dose, when taken and 211 
for what reason.’). This researcher-created questionnaire has no reliability/sensitivity measures and 212 
was utilized solely as a tool to detect any gross changes in the consumption patterns of participants 213 
which might affect outcome measures. The researcher noted no salient dietary or medication 214 
changes across the study for any of the participants. 215 
General Health Questionnaire (GHQ): 216 
The GHQ
(30)
 utilized in the current study was the 28-item scaled version which assesses somatic 217 
symptoms, anxiety and insomnia, social dysfunction and severe depression. The 28 items are scored 218 
from 0-3 with participants indicating the frequency or extent to which they have experienced a 219 
number of issues, such as ‘Have you recently been having hot or cold spells?’, in the previous week. 220 
The items combine to assess the 4 aforementioned sub-scales and the total possible score (when 221 
these 4 sub-scales are collated) ranges from 0- 84; with higher scores representing more negative 222 
symptoms.  223 
Profile Of Mood States (POMS): 224 
The POMS is a well validated questionnaire of mood states and their fluctuations both in the 225 
clinical and research setting
(31)
. Participants rated 65 adjectives (e.g. unhappy, considerate), in terms 226 
of how much they had felt each one in the past week, utilizing a 5-point scale from ‘not at all’ to 227 
‘extremely’. Scores from these 65 items (which includes 7 dummy adjectives) are combined to give 228 
6 global scores of ‘tension’, ‘depression’, ‘anger’, ‘fatigue’, ‘confusion’ and ‘vigour’. A total mood 229 
disturbance score can also be calculated by adding the scores from the first 5 of these global scores 230 
and subtracting ‘vigour’. 231 
Pittsburgh Sleep Quality Inventory (PSQI): 232 
The PSQI is a well validated subjective measure of the quality and pattern of sleep
(32)
. The current 233 
study tailored this questionnaire to assess sleep during the past ‘week’ rather than ‘monthly’ as per 234 
the original. The PSQI assesses 7 factors: subjective sleep quality; sleep latency; sleep duration; 235 
habitual sleep efficiency; sleep disturbances; use of sleep medication and daytime dysfunction, via 236 
questions regarding sleep timings and 0-3- point scales where participants rate whether they have 237 
experienced a number of issues (e.g. ‘During the past week, how often have you had trouble 238 
sleeping because you have had bad dreams?’) from ‘not during the past week’ to ‘3 or more times in 239 
the past week’. A global sleep score is created by totalling the 7 sub-factor scores with higher scores 240 
indicating poorer sleep quality. 241 
 242 
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Treatment guess 243 
During the day 28 visit participants were asked to guess which treatment they thought they had been 244 
taking for the duration of the study and to explain any reasons for that guess. 245 
 246 
Procedure 247 
This investigation required participants to attend the laboratory for an initial training/ screening 248 
session and then on 2 separate occasions, 28 days apart, for laboratory-based testing sessions. 249 
Participants were required to supplement themselves with 1 capsule per day in the interim. 250 
Upon arrival at both day 1 and day 28 lab visits participants completed 4 questionnaires: a food 251 
consumption questionnaire; the GHQ; POMS; and the PQSI. All questionnaires were answered in 252 
relation to the previous 7 days and completed every 7 days during the supplementation period. After 253 
filling in the questionnaires, participants then gave a blood pressure reading or an intravenous blood 254 
sample (15 participants provided blood samples- see below for more information and the 255 
demographics of the 7 participants from the resveratrol condition entered into the analysis) which 256 
was immediately followed by a 5 minute rest. A 5 minute recording of cerebral perfusion in the 257 
MCA was then taken with TCD. The NIRS headband was then positioned onto the forehead of the 258 
participant to monitor CBF in the prefrontal cortex throughout the session. Once a reliable trace was 259 
identified participants commenced 20 minutes (x2 repetitions of the battery) of baseline cognitive 260 
tasks. The first of these repetitions acted as a ‘refresher’, attenuating any practice effects, and the 261 
second was utilized to create change from baseline data for the analysis of cognitive outcome data. 262 
A 10 minute rest period then followed with NIRS data averaged across this period and used as an 263 
accurate, immediately pre-treatment baseline for the calculation of change from baseline data for 264 
the post-treatment periods. During this 10-min resting period participants watched a non-arousing 265 
DVD. Participants then consumed the first day’s treatment and continued to watch the DVD for a 266 
further 40 minute absorption period. After this period a blood pressure reading was taken in those 267 
who did not provide a blood sample previously and 40 minutes of post-dose tasks commenced. 268 
After task completion a further blood pressure reading was taken from the relevant participants and 269 
followed by a short break before the 2
nd
 TCD recording was conducted. Following the TCD 270 
recording participants were either free to leave the lab or provided a final blood sample if they were 271 
part of the aforementioned sub-section of participants. The timelines and running order of the 272 
testing sessions are shown in figure 1. 273 
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 274 
Figure 1. Day 1 and 28 esting session timeline. Upon arrival participants completed 4 questionnaires (a 275 
food consumption questionnaire, the GHQ, POMS and the PQSI) which they answered in relation to the 276 
previous 7 days and completed every 7 days during the supplementation period. Participants then gave a 277 
blood pressure reading or an intravenous blood sample which was immediately followed by a 5min rest. A 278 
5min recording of cerebral perfusion in the MCA was then taken with the TCD. The NIRS headband was 279 
then positioned and 20min of baseline tasks commenced. A 10min rest then followed during which 280 
participants watched a non-arousing DVD. Participants then consumed their treatment capsule and continued 281 
to watch the DVD for a further 40min absorption period. A blood pressure reading was then taken from a 282 
sub-sample of participants and 36mins of post-dose tasks commenced. The NIRS headband was removed 283 
and a further blood pressure reading taken, followed by a short break, before the 2
nd
 TCD recording was 284 
conducted. Following the TCD recording the aforementioned sub-section of participants provided a blood 285 
sample and left the lab.  286 
 287 
Bioavailability assessment 288 
Participants:  289 
Complete sample sets comprising all 4 time-points were obtained from 15 participants (8 from 290 
placebo and 7 from resveratrol; 10 females, 5 males; mean age 19.87 years; range 18-25 years). All 291 
participants were asked, at the beginning of the study, if they would provide blood samples as part 292 
of the investigation: the above 15 participants represent those who agreed to this aspect of the study 293 
and for whom all 4 samples could be collected in full. The 7 resveratrol participants included in the 294 
analysis comprised: 6 females, 1 male; mean age 19.43 years, range 18-21 years. 295 
Venous blood samples were collected before the days treatment was consumed and 110-minutes 296 
post-dose in this sub-sample of participants using 4.7ml monovettes (Sarstedt AG & Co) containing 297 
lithium heparin. Samples were centrifuged at 2500rpm for 15 minutes at 20
o
C to yield plasma, 298 
which was then stored at -80
o
C until analysis. 299 
 
Minutes post-treatment
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The preparation of Samples and LC-MS analysis is as per a previous study conducted by this lab 300 
(33)
. 301 
 302 
Statistics 303 
The analyses of TCD, plasma, questionnaire, behavioural and treatment guess data were conducted 304 
with IBM SPSS Statistics 19.0 for Windows (SPSS Inc, Chicago, IL). NIRS data was analysed with 305 
Minitab 16 for Windows (Minitab Inc, State College, PA). 306 
Questionnaire data analysis: 307 
Questionnaire data (GHQ, POMS and PSQI) for each of the four post-dose weekly completions was 308 
analysed as change from baseline (the questionnaire scores obtained on day-1 prior to treatment) for 309 
each individual variable/sub-component by a mixed (Day (x4): 7, 14, 21, 28, by Treatment (x2): 310 
500mg resveratrol and placebo) ANOVA with Bonferroni corrected post-hoc student t tests 311 
conducted if a significant main and/or interaction effect was evinced here. 312 
Treatment guess analysis: 313 
Treatment guess data was analysed by Chi-Square. 314 
Trans-cranial Doppler (TCD):  315 
The raw data for each of the four TCD variables (Mean Velocity, Peak Systolic Velocity, Diastolic 316 
Velocity and Pulsatility Index) were analysed by a mixed (Treatment (x2): 500mg resveratrol and 317 
placebo, by time (x4): baseline day 1, post-dose day 1, pre-dose day 28 and post-dose day 28) 318 
ANOVA. 319 
Plasma analysis: 320 
The raw data for each of the four forms of plasma resveratrol (resveratrol-3-sulfate, resveratrol-4-321 
glucuronide, resveratrol-3-glucuronide and ‘total metabolites’; which is the sum of the three 322 
metabolites) was analysed via ANOVA with time as a factor (x4: baseline day 1, post-dose day 1, 323 
pre-dose day 28 and post-dose day 28). 324 
Cognitive task data and Blood Pressure (BP) analysis:  325 
The cognitive task and BP measures produce data that can be analysed to assess both acute 326 
(potential treatment effects within day 1), pure-chronic (chronic treatment-related effects which 327 
have taken place across the 28 day supplementation period but prior to taking the day 28 treatment) 328 
and superimposed acute/chronic (the difference in ‘acute’ effects between day 1 and day 28) effects 329 
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of resveratrol. In order to adequately analyse the ‘acute’, ‘pure chronic’ and ‘superimposed 330 
acute/chronic’ effects of the treatments 2 separate ANOVAs were conducted: 331 
1. Pure chronic effects: 332 
To ascertain if any pure chronic effects of resveratrol supplementation had taken place, pre-dose 333 
data on day 28 was converted to change from day 1 pre-dose baseline and analysed via one-way 334 
ANOVA to compare performance between treatments. 335 
2. Acute, chronic and superimposed effects: 336 
To ascertain if any acute and/or superimposed chronic effects of resveratrol supplementation had 337 
taken place, data was converted to change from baseline with respect to the pre-treatment scores on 338 
the first day of treatment (day 1) and analysed via a repeated measures ANOVA (treatment 339 
(resveratrol/ placebo, X repetition (x4 for cognitive data and x2 for BP), by day (day 1/28). 340 
Both ANOVAs were utilized in order to tease apart acute effects restricted to day 1 (treatment x day 341 
interactions with significant effects restricted to day 1), acute effects across both day 1 and day 28 342 
(main effect of treatment and/or a treatment x repetition interaction) and a superimposed 343 
acute/chronic effect (treatment x day interaction with significant effects restricted to day 28 344 
(interpreted with reference to the pure chronic ANOVA results)). If any such main and/or 345 
interaction effects were observed then Bonferroni corrected post-hoc student t tests were conducted 346 
to assess where these differences lie. This analysis plan has proven sensitivity in detecting the acute 347 
and chronic effects of ginseng in healthy, human participants previously
(34)
. 348 
Near-Infrared Spectroscopy analysis: 349 
NIRS data was converted to ‘change from baseline’ (calculated from the 10 minute pre-treatment 350 
resting period) and averaged across 2 minute epochs during the 40 minute ‘rest/absorption’ and 40 351 
minute cognitive task performance period. Analysis of variance (treatment group x 2min epoch x 352 
day) was conducted on this data with planned comparisons of data from each epoch being made 353 
between placebo and 500mg resveratrol (resulting in 40 planned comparisons for oxy-HB, Deoxy-354 
Hb and total-Hb) using t tests calculated with the Mean Squares Error from the ANOVA
(35)
. A 355 
significant result on this ANOVA was not used as a prerequisite for carrying out and interpreting 356 
the planned comparisons and are, therefore, not presented here. However, in order to reduce the 357 
potential for Type I errors, all planned comparisons were Bonferroni corrected and only those 358 
planned comparisons associated with a consistent pattern of significant effects are interpreted and 359 
reported herein.  360 
 361 
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RESULTS 362 
Compliance 363 
Potential compliance ranged from 0-114% (the upper limit reflecting 32 capsules consumed over 28 364 
days). Average compliance was 101% with a range of 78.5-114.3%. Data from one participant with 365 
78.5% compliance (who provided blood samples in the placebo condition only) was excluded from 366 
analysis, due to being below a pre-set level of 80%, making average compliance 101.4% with a 367 
range of 92.9%-114.3%. 368 
Treatment guess 369 
Chi-Square revealed no significant difference between treatment guesses in the 2 treatment groups: 370 
χ2= .766; df= 1; p= .381. 371 
NIRS parameters 372 
Total haemoglobin (total-Hb): 373 
Planned comparisons revealed that, on day 1, levels of total-Hb were significantly higher after 374 
resveratrol, compared to placebo, during the 2-minute epochs spanning 35-38 min post-dose 375 
(35/36min [p=0.003], 37/38 min [p=0.008]) of the absorption period and the epochs spanning 75-78 376 
min (75/76 min [p=0.008], 77/78 min [p=0.005] of the post-dose task period. No significant 377 
differences were found between resveratrol and placebo on day 28. 378 
Oxygenated haemoglobin (oxy-Hb): 379 
Planned comparisons revealed that, on day 1, levels of Oxy-Hb were significantly higher in the 380 
resveratrol condition, compared to placebo, during the 2-min epochs commencing 23 [p=0.002], 27 381 
[p=0.005], 33 [p=0.002], 35 [p=0.001] and 37 [p=0.009] min post-dose of the absorption period and 382 
the epochs spanning 41-44 mins (41/42 min [p=0.006]), 43/44 min [p=0.001]), 53-54 min 383 
[p=0.001], 61-68 min [p= 0.0008; 0.001; 0.007 and 0.001 respectively], 71-72 min [p=0.003], and 384 
75-78 min (75/76 min [p=0.0002], 77/78 min [p=0.0002]) of the post-dose task period. No 385 
significant differences were found between resveratrol and placebo on day 28. 386 
Deoxygenated haemoglobin (deoxy-Hb): 387 
Planned comparisons revealed that, on day 1, levels of deoxy-Hb were significantly higher in the 388 
placebo condition, compared to resveratrol, during the  2-minute epochs commencing 27 [p=0.001], 389 
29 [p=0.006] and 35 [p=0.003] min post-treatment in  the absorption period and the epochs 390 
commencing 43 min [p=0.004] min, and spanning 51-54 min (51/52 min [p=0.0002], 53/54 min 391 
[p=0.004], and those spanning 61-72 min (61/62 [p=0.001], 63/64 [p = 0.003], 65/66 [p = 0.0005], 392 
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67/68 ; [p = 0.002], 69/70 [p = 0.004], 71/72 [p = 0.0008] respectively) and those spanning 75-80 393 
min 75/76 [p=0.001], 77/78 [p = 0.003] 79/80 [p = 0.004] respectively) of the post-dose task period. 394 
No significant differences were found between resveratrol and placebo on day 28. 395 
Mean total-, oxy- and deoxy-Hb levels for placebo and resveratrol, across day 1 and day 28, are 396 
shown in figure 2. 397 
 398 
Figure 2. Concentration changes from baseline in levels of (top) total Hb (Total-Hb), (middle) 399 
oxygenated Hb (Oxy-Hb) and (bottom) deoxygenated Hb (Deoxy-Hb). Data averaged across two-min 400 
epochs during a 40-min absorption period and subsequent 40 min of cognitive task performance following 401 
placebo or 500 mg of resveratrol on day 1 and day 28 (n 46).     , Placebo;     , 500 mg of resveratrol. Values 402 
are means, with standard errors represented by vertical bars. Significance planned comparisons (Bonferroni 403 
corrected) between resveratrol and placebo of data from each 2-min epoch: * P<0·05 and ** P <0·01. 404 
 405 
 406 
 407 
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TCD parameters 408 
No significant acute chronic or gross chronic effects were observed with any of the 4 TCD 409 
parameters (Mean velocity; Peak systolic velocity; Diastolic velocity; and Pulsatility index).  410 
Cognitive task performance  411 
1. Pure chronic ANOVA 412 
The results of the ANOVA on day 28 pre-dose data (converted to change from day 1 baseline) 413 
comparing performance between 500mg resveratrol and placebo, demonstrated a significant effect 414 
of treatment for the 3-Back task in terms of the  % of correct responses (F (1,40)= 8.60, p=.006) 415 
with better performance in the resveratrol condition as compared to placebo. 416 
2. Acute, chronic and superimposed ANOVA 417 
The results of the treatment x repetition x day ANOVA are as follows. Note that, for brevity, only 418 
those significant main and/or interaction effects involving treatment are described here but see 419 
supplementary materials for all ANOVA F and P value tables. 420 
7s incorrect: Analysis revealed a main effect of treatment (F (1, 39)= 6.40, p=0.016) (with the 421 
mean for number of serial 7s incorrect responses for placebo, overall, higher than the mean for 422 
500mg resveratrol) and a day x repetition x treatment interaction (F (3, 117)= .260, p=0.034). Post-423 
hoc comparisons (Bonferroni corrected) revealed a significant difference on day 1 at repetition 4 424 
(p=.005) and trends for differences on day 1 at repetition 2 (p= .073) and on day 28 at repetition 3 425 
(p= .070). The mean number of incorrect responses was lower in the 500mg resveratrol condition in 426 
all 3 cases.  427 
17s correct: The ANOVA revealed an interaction between day x treatment x repetition (F (3, 117)= 428 
3.45, p=0.019). Post-hoc comparisons revealed significant differences on day 28 at repetition 1 and 429 
repetition 3 (both p=0.04) with the mean number of serial 17s correct completions higher in the 430 
placebo condition in both cases.  431 
17s incorrect: The ANOVA showed a main effect of treatment (F (1, 39)= 5.79, p=0.021) (with the 432 
mean number of 17s subtraction incorrect responses, overall, higher in the placebo condition as 433 
compared to 500mg resveratrol). An interaction between repetition x treatment (F (3, 117)= 3.55, 434 
p=0.017) was also observed. With regards the repetition x treatment interaction, post-hoc 435 
comparisons revealed only one significant comparison between treatments at the 4th repetition on 436 
day 28. Here the mean number of incorrect responses was higher (p=0.003) in the placebo 437 
condition.  438 
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General health 439 
There were no significant treatment related differences on the General Health Questionnaire (GHQ) 440 
or its subcomponents. 441 
Sleep 442 
There were no significant treatment related differences on the Pittsburgh Sleep Quality Index 443 
(PSQI) or its subcomponents. 444 
Mood 445 
A significant treatment effect was observed for the ‘fatigue’ measure alone (F (1, 52)= 9.37, p= 446 
0.003); derived from the Profile of Mood States (POMS) questionnaire. Further analysis with 447 
Bonferroni corrected post-hoc student t tests demonstrated that subjective ratings of fatigue were 448 
significantly lower for resveratrol on day 7 (p=0.04), day 21 (p=0.013) and day 28 (p=0.001). A 449 
move towards a trend was also evinced for day 14 (p=.097). See supplementary materials for 450 
average weekly ratings on POMS questionnaire and ANOVA F and P value tables.  451 
Blood pressure 452 
1. Pure chronic ANOVA 453 
The results of the ANOVA on day 28 pre-dose BP measurements (converted to change from day 1 454 
baseline) comparing readings between 500mg resveratrol and placebo, demonstrated only a 455 
significant effect for diastolic BP (F (1, 28)= 5.86, p=0.022) with levels higher in the resveratrol 456 
condition. 457 
2. Acute, sub-chronic and superimposed ANOVA 458 
No significant effects were observed for systolic BP or HR. For diastolic BP, a significant 459 
interaction between treatment x day was evinced (F (1, 22)= 6.61p=0.017) which revealed only 1 460 
significant comparison, in the placebo condition, between day 1 and day 28, at the 40 minutes PD 461 
measurement (p=0.46). Here the mean was higher overall on day 28 compared to day 1. 462 
See supplementary materials for BP values and ANOVA F and P value tables. 463 
 464 
Plasma analysis (total metabolite levels) 465 
A significant effect of time was observed (F (1.35, 8.10)= 7.50, p= 0.02) for levels of total 466 
resveratrol metabolites (the sum of Resveratrol 3-O-sulfate and Resveratrol 4’- and 3-O-467 
glucuronides) with pairwise comparisons revealing that day 1 post-dose levels were higher than day 468 
1 baseline (p=0.023), that day 28 pre-dose levels were higher than day 1 baseline (p=0.033) and that 469 
day 28 post-dose levels were higher than both day 1 baseline (p=0.003) and day 28 pre-dose levels 470 
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(p=0.005). All 3 metabolites followed this same pattern of significance and so, for brevity, only 471 
total metabolite levels are reported here. 472 
No resveratrol (in any form) was found in baseline samples on day 1, indicating that all volunteers 473 
did not consume resveratrol containing products before the study. No aglycone resveratrol was 474 
quantifiable in plasma at any time-point, on either day. Resveratrol 3-O-sulfate was the 475 
predominant metabolite in all volunteers, contributing 73-77% of total metabolites. The 4’- and 3-476 
O-glucuronide forms evinced roughly equal contributions to the remaining metabolites in 477 
circulation.  478 
Mean plasma concentration values (µM) for resveratrol metabolites at baseline and post-dose (110 479 
minutes after administration) on day 1 and, after daily 500mg consumption, on day 28 shown in 480 
figure 3. 481 
 482 
 483 
Figure 3. Mean plasma concentration (µM) values (±SEM) of resveratrol metabolites in plasma at 484 
baseline and post-dose (110mins post administration) on day 1 and day 28 (N=7). Graph displays mean 485 
plasma concentration (µM) values (with SEM error bars) of resveratrol metabolites in plasma at baseline and 486 
post-dose (110mins post administration) on day 1 and day 28, after 500mg trans-resveratrol, in 7 healthy, 487 
young adults. Significance on graph demonstrated for total metabolites, with * (P=<.05) and ** (p=<.01), 488 
although all 3 metabolites demonstrate the same pattern.  489 
 490 
 491 
 492 
 493 
 494 
18 
 
DISCUSSION 495 
In summary, the results here show that whilst a single dose of 500mg trans-resveratrol can 496 
modulate CBF parameters in the frontal cortex in a pattern consistent with increased blood flow, 497 
supplementation for 28 days does not result in any clear improvements in cognitive function, 498 
despite an increase in plasma metabolites levels. However, there was evidence of significantly 499 
reduced fatigue and higher diastolic BP following extended supplementation. No modulation of 500 
subjective sleep quality, health or chronic CBF was observed.  501 
The chronic 28 day dosing paradigm utilized in the current paper was designed to address the 502 
potential ineffectiveness of resveratrol at eliciting cognitive performance effects after acute, bolus 503 
supplementation
(2, 33)
. The hypothesis being that chronic consumption of resveratrol might increase 504 
exposure to resveratrol; a polyphenol with known low bioavailability following acute 505 
administration
(9)
. This increased exposure may be expected to enhance the biological activity of 506 
resveratrol; specifically, of importance here, those with direct and/or indirect effects on cognitive 507 
function. However, analysis demonstrated that the only cognitive task measure to evince a pure 508 
chronic effect (derived by the comparison of changes in performance between resveratrol and 509 
placebo between day 1 baseline and day 28 pre-dose) was N-Back % correct: i.e. after 28 days 510 
supplementation, participants in the 500mg resveratrol condition completed significantly more 511 
correct 3-Back responses before taking their day’s treatment, as compared to placebo. No effects on 512 
this measure were observed following consumption of treatment on day 1 or day 28 nor were any 513 
effects observed on the other accuracy sub-measure assessed here. The results of acute and 514 
chronic/superimposed analysis revealed that, on day 28, participants in the resveratrol condition 515 
performed slower, achieving less correct responses on the serial 17 subtractions task. However, on 516 
day 1 and day 28, participants in the same condition also performed more accurately (less incorrect 517 
responses) on the serial 7 and serial 17 subtraction tasks. Whilst these results suggest a speed 518 
accuracy trade-off, closer inspection of these significant main effects highlights an inconsistent and 519 
difficult to interpret pattern, with the effects on the serial 7 task restricted to the 4
th
 task battery 520 
repetition on day 1 only and the 1
st
, 3
rd
 and 4
th
 repetitions, on day 28, for the effects on the serial 17 521 
subtraction task; where both higher and lower performance was seen in the resveratrol condition. 522 
Due to the lack of any clear pattern of results in both the acute and chronic effects of resveratrol on 523 
cognition here (and indeed the previous two studies assessing the effects of resveratrol on cognitive 524 
function), it is important to regard these results with caution. It may be that the relatively small 525 
sample here is masking a real effect, or a clearer effect, of resveratrol or it may be that a number of 526 
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type I errors have inflated expectations. Nevertheless, only a tightly controlled, crossover study with 527 
greater power would be able to address this issue. 528 
The current study demonstrates that 500mg trans-resveratrol is able to augment the CBF response 529 
to cognitive task demands, relative to placebo, after acute, oral, administration to healthy human 530 
participants. This acute augmentation manifested in small, significantly higher levels of total-Hb, 531 
indicative of increased CBF, at the ends of the absorption- and post-dose task periods and a 532 
consistent pattern of significantly higher levels of oxy-Hb across some of the absorption- and post-533 
dose task periods following the first dose of resveratrol on day 1. Levels of deoxy-Hb were also 534 
significantly lower in the resveratrol condition, as compared to placebo. This latter finding is 535 
directly opposite to that reported previously
(2, 33)
 and is contrary to the hypothesis that resveratrol 536 
would facilitate increased oxygen extraction due to its reported effects on oxidative 537 
phosphorylation
(36)
. No clear reason for this anomalous finding can be offered at present but it may 538 
be notable that whilst the previous two aforementioned resveratrol/NIRS studies by this lab were 539 
crossover studies, the current is the first to utilize a between-subjects design and this may introduce 540 
an unanticipated degree of variability in CBF parameters. In contrast to day 1, the consumption of 541 
the resveratrol treatment on day 28 was not found to have an acute effect on any of the CBF 542 
parameters. As noted above, CW-NIRS generates concentration change, rather than quantitative 543 
data, and therefore only provides a measure of acute changes in haemodynamics during each 544 
discrete recording session. It therefore provides no direct measure of any changes that have taken 545 
place between recording sessions, in this case as a consequence of chronic resveratrol 546 
supplementation. The lack of an effect here may then reflect several distinct possibilities. It may, of 547 
course, reflect a simple attenuation of the acute effects seen following the first dose of resveratrol 548 
on day 1. However, it could equally reflect either the raised levels of resveratrol metabolites seen 549 
pre-treatment on day 28, which may have precluded a further acute effect of an additional dose on 550 
day 28; or it may indicate that a gross (undetected) change in CBF parameters had already taken 551 
place, attenuating the possibility of any additional acute effects of day 28’s treatment. 552 
In the current study, TCD was also incorporated to provide a measure of chronic CBF. This 553 
technique provides an absolute quantitative measure of CBF, (in this case as indexed by CBF 554 
velocity (CBFV) in the right middle cerebral artery) which was intended to elucidate any gross 555 
chronic changes in CBF as a consequence of resveratrol supplementation. No significant changes in 556 
CBFV were observed with TCD, suggesting a simple absence of modulation of CBF by resveratrol 557 
However, this interpretation should be tempered by several considerations. The first is that the 558 
recording period was much shorter (at 5 minutes) than for NIRS and it was undertaken entirely at 559 
20 
 
rest, with no data collected during the period of task-performance during which resveratrol has been 560 
shown to have its most pronounced effects. Secondly, whilst the NIRS was used to measure local 561 
changes in CBF in the upper layers of the frontal cortex during tasks which activate this brain area, 562 
the right middle cerebral artery supplies the entire right side of the cortex. Given this, any 563 
vasodilatory effects restricted to the locality of neural activity (in this case the prefrontal cortex) 564 
may have been swamped in the gross blood flow. Potential reasons for a lack of significant CBFV 565 
changes include the relatively short recording period with the TCD: 5 minutes, yielding only 2 566 
measurements per minute, which may simply be to narrow a window to detect effects. The TCD 567 
recording periods were also conducted during times of minimal cognitive demand (pre and post the 568 
cognitive task periods) and, as such, metabolic substrate demands would have been less during 569 
these periods and an increase in the hemodynamic response unnecessary. Ideally the TCD and 570 
NIRS would both have been used to record concomitantly throughout the absorption and cognitive 571 
task periods. Unfortunately, due to the physical constraints of the equipment utilized here, this was 572 
not possible. 573 
The current study does, however, report vascular effects of resveratrol in the periphery on day 28; 574 
with the analysis of pure chronic effects (derived by comparing change from day 1 baseline BP 575 
measurements between resveratrol and placebo to pre-treatment on day 28) demonstrating higher 576 
diastolic BP in resveratrol-supplemented participants. No pre-treatment baseline differences in BP 577 
readings, nor acute effects of treatment within day 1 or day 28 were observed. This finding is 578 
intuitively unexpected as resveratrol has previously been shown to be a vasodilator
(6, 37)
; a 579 
phenomenon associated with lowered BP. Whether resveratrol can act as a vasoconstrictor is, at 580 
present, unknown but it may be noteworthy that structurally similar polyphenols, such as the tea 581 
polyphenol epigallocatechin-3-gallate (EGCG), can act both as both vasodilators and 582 
vasoconstrictors depending on dose and the time of assessment
(38)
. EGCG has also been 583 
investigated with regards its cognitive and CBF effects in humans, with a single dose of 135mg, 584 
leading to a significant reduction in CBF as compared to placebo; which might indeed be suggestive 585 
of vasoconstriction. 586 
No significant differences between treatments, or within-treatment changes, were observed with 587 
subjective perceptions of general health (as assessed by the GHQ) or sleep (as assessed by the 588 
PSQI). With regards subjective perceptions of mood, the only variable on the POMS questionnaire 589 
which evinced any significant difference was ‘fatigue’ which remained significantly lower across 590 
the entire 28 day period in the resveratrol condition, as compared to placebo. Little research exists 591 
regarding the effects of polyphenols on mood but this anti-fatigue effect may find an explanation in 592 
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in vitro and animal work which reports the ability of resveratrol to inhibit Monoamine Oxidase-A 593 
and B (MAO-A/B) activity. This inhibition was reported to lead to an increase in monoamine 594 
neurotransmitter concentrations, namely 5-hydroxytryptophan (5-HT), noradrenaline and dopamine, 595 
with a concomitant improvement in mood; similar to that seen with imipramine and fluoxetine, in 596 
mice
(18)
. Interestingly quercetin, another red wine polyphenol, also shows anti-fatigue activity 597 
through increased energy expenditure and endurance capacity in mice
(39, 40 respectively)
 and power 598 
output in elite male cyclists when part of a cocktail of supplemented compounds
(41)
. Mechanisms 599 
include increased blood flow; due to vasorelaxation
(42)
, and oxygenation; with Davis et al.
(40)
 also 600 
reporting SIRT-mediated increases in mitochondrial gene expression in brain and skeletal muscles. 601 
Both mechanisms are shared with resveratrol
(36, 42)
 and could explain the increased energy levels 602 
seen here. It is worth noting here that, whilst there was no statistically significant difference in 603 
baseline (pre-dose on day 1) levels of fatigue between resveratrol and placebo participants, the 604 
baseline values were nevertheless numerically higher in the former group (8.04 compared to 5.54 605 
respectively) which might suggest that this effect represents a return to normal levels for the 606 
resveratrol group following an unusually high baseline.  607 
Analysis of the plasma samples, taken from a sub-sample of 7 participants from the resveratrol 608 
condition on day 1, demonstrated increases in acute resveratrol metabolite levels post-dose very 609 
similar to those seen in a previous study conducted by this lab
(2)
. Pre-dose levels of metabolites on 610 
day 28 were also significantly higher than those seen pre-dose on day 1, suggesting that chronic 611 
consumption results in an accumulation of resveratrol metabolites in plasma. They subsequently 612 
increased following day 28’s treatment, and again ended at a significantly higher level than post-613 
dose on day 1.  Pre- and post-dose levels of resveratrol on day 28 were significantly higher than 614 
baseline levels on day 1 and, within day 28, post-dose levels were significantly higher than pre-dose 615 
levels. Taken together, these findings suggest (hence their presence prior to treatment 616 
administration on day 28), and that this may amplify the increase following acute administration 617 
(hence numerically higher levels at day 28 post-dose compared to day 1 post-dose). That the day 1 618 
baseline mean levels were 0 does render this comparison, statistically, problematic. However, 619 
disregarding statistical significance, the fact that metabolites were present on day 28 at all 620 
(considering that levels were 0 at baseline on day 1) is indicative that an increase in plasma levels of 621 
resveratrol had taken place. This novel finding of accumulating levels of resveratrol metabolites as 622 
a consequence of chronic administration certainly warrants further investigation with larger 623 
samples, as previous acute dose research does not suggest that plasma metabolites should still be 624 
present beyond 24hrs
(9)
, or certainly not at the levels seen here at pre-dose on day 28
(10)
. It may be 625 
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possible that these effects are the result of some other, unknown factor/s; for instance the 626 
consumption by participants of more resveratrol containing products or an additional resveratrol 627 
capsule prior to attending the laboratory on day 28. However, this seems unlikely, and is argued 628 
against by the participants’ treatment diaries and a capsule count.   629 
The methodology of the current study had a number of strengths and limitations. The nature of the 630 
paradigm; namely the timeframe involved and the use of equipment which dictates individual 631 
testing (i.e. the NIRS and TCD), necessarily means that the sample size is somewhat restricted for 632 
outcome measures like cognitive performance which ideally require a larger sample than the 633 
physiological measures. In this study the issue was exacerbated by the loss of a number of sets of 634 
data (due largely to an equipment failure) which reduced the number of cognitive performance data 635 
sets. This renders interpretation of the cognitive data more difficult, but an argued strength of this 636 
paper is the caution with which the authors have regarded such data. Another limitation relates to 637 
the equipment utilized here to measure CBF. As noted above CW-NIRS only generates acute 638 
concentration change data, and therefore the question that it was used to address on day 28 of the 639 
current study was: “Are the acute haemodynamic effects of the single dose of resveratrol taken on 640 
day 28 the same, or different, to those seen following the first dose taken on day 1”. The results 641 
showed that there were no acute effects on day 28, so they were different. However, the difficulty in 642 
interpreting this finding further is that this could reflect an attenuation of the acute effects over time, 643 
but it could equally be the result either of the raised levels of resveratrol metabolites already seen 644 
prior to taking the day 28 treatment, or indeed unmeasured chronic effects on CBF. To address the 645 
last of these points TCD was incorporated as a measure of chronic changes of absolute CBFV, but 646 
this measure showed no effect- although again this could be due to methodological issues (including 647 
measuring at rest, rather than during task performance, and the diffuse rather than local nature of the 648 
measurement). It would therefore be advantageous to revisit the question of the chronic effects of 649 
resveratrol on CBF using the more recently introduced ‘quantitative’ NIRS, which, as the name 650 
suggests, generates quantitative, rather than concentration change data. In terms of strengths, the 651 
current paper incorporated a range of methodologies in order to answer the, hitherto unaddressed 652 
question, as to whether resveratrol can engender chronic cognitive effects. This is also the first 653 
paper to show that repeated consumption of resveratrol can lead to cumulative plasma levels at a 654 
dose which is recommended by many over-the-counter resveratrol products. 655 
In conclusion, the current study reports that chronic, 28 day supplementation of 500mg trans-656 
resveratrol results in significantly reduced fatigue and higher diastolic BP, but does not modulate 657 
sleep, health or chronic CBF. The single, chronic, cognitive effect evinced by resveratrol and the 658 
23 
 
confusing pattern of acute effects, should be treated with caution. This study is the first to suggest 659 
that chronic resveratrol consumption could result in cumulative plasma levels in healthy humans 660 
after oral administration. 661 
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